Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Boron containing doai
Reexamination Certificate
2008-09-23
2008-09-23
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Boron containing doai
C514S114000, C514S622000
Reexamination Certificate
active
11395937
ABSTRACT:
The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.
REFERENCES:
patent: 5464861 (1995-11-01), Dobrusin et al.
patent: 5532167 (1996-07-01), Cantley et al.
patent: 5552534 (1996-09-01), Hirschmann et al.
patent: 5648378 (1997-07-01), Huang
patent: 5705585 (1998-01-01), Hogan, Jr.
patent: 5736412 (1998-04-01), Zambias et al.
patent: 6011175 (2000-01-01), Sebti et al.
patent: 6420338 (2002-07-01), Schneider et al.
patent: 6552066 (2003-04-01), Sharpe et al.
patent: 7005445 (2006-02-01), Hangauer et al.
patent: 7070936 (2006-07-01), Hangauer, Jr. et al.
patent: 7129225 (2006-10-01), Nicotera et al.
patent: 2003/0016615 (2003-01-01), Lee et al.
patent: 2004/0019015 (2004-01-01), Nicotera et al.
patent: 2006/0030544 (2006-02-01), Hangauer, Jr. et al.
patent: 2006/0089401 (2006-04-01), Hangauer, Jr. et al.
patent: 2006/0172971 (2006-08-01), Nicotera et al.
patent: 2008/0004241 (2008-01-01), Hangauer
patent: 43 07 883 (1993-09-01), None
patent: 0 846 464 (1998-06-01), None
patent: 0 370 381 (1990-05-01), None
patent: WO 91/09849 (1991-07-01), None
patent: WO 96/35805 (1996-11-01), None
patent: WO 96/39384 (1996-12-01), None
patent: WO 96/39385 (1996-12-01), None
patent: WO 98/27108 (1998-06-01), None
patent: WO 00/42213 (2000-07-01), None
patent: WO 01/85726 (2001-11-01), None
patent: WO 02/072548 (2002-09-01), None
patent: WO 03/093297 (2003-11-01), None
Huang et al., “Polyhydroxylated 3-(N-Phenyl) Carbamoyl-2-Iminochromene Derivatives as Potent Inhibitors of Tyrosine Kinase p60c-src,”Bioorganic&Medicinal Chemistry Letters, 5(20):2423-2428 (1995).
Levitzki et al., “Tyrosine Kinase Inhibition: An Approach to Drug Development,”Science, 267:1782-1788 (1995).
Lawrence et al., “Protein Kinase Inhibitors: The Tyrosine-Specific Protein Kinases,”Pharmacol. Ther., 77(2):81-114 (1998).
Lai, et al., “The Design, Synthesis and Activity of Pentapeptide pp60c-srcInhibitors Containing L-phosphotyrosine Mimics,”J. Peptide Res., 51:271-281 (1998).
Kennedy, “Role of Protein Tyrosine Phosphatase-1B in Diabetics and Obesity,”Biomedicine&Pharmacotherapy, 53(10):466-470 (1999) (Abstract).
Biscardi, et al., “c-Src, Receptor Tyrosine Kinases and Human Cancer,”Advances in Cancer Research, 61-119 (1999).
“Amersham Pharmacia Biotech to Market and Distribute BioFocus' SoftFocus(TM) Kinase Libraries in North America,” News release: Nov. 23, 1999.
Ripka, “Chapter 21. Protein Tyrosine Phosphatase Inhibition,”Annual Reports in Medicinal Chemistry, 35:231-250 (2000) (Abstract).
Pestell, et al., “Small Molecule Inhibitors of Dual Specificity Protein Phosphatases,”Oncogene, 19(56):6607-6612 (2000) (Abstract).
Moller, et al, “Protein Tyrosine Phosphatases (PTPs) as Drug Targets: Inhibitors of PTP-1B for the Treatment of Diabetes,”Current Opinion in Drug Discovery&Development, 3(5):527-540 (2000) (Abstract).
Irby et al., “Role of Src Expression and Activation in Human Cancer,”Oncogene, 19:5636-5642 (2000).
Garcia-Echeverria, et al., “ATP Site-Directed Competitive and Irreversible Inhibitors of Protein Kinases,”Med. Res. Rev., 20(1):28-57 (2000).
Abram, et al., “Src Family Tyrosine Kinases and Growth Factor Signaling,”Experimental Cell Research, 254:1-13 (2000).
Marsilje, et al., “The Design, Synthesis and Activity of Non-ATP Competitive Inhibitors of pp60c-srcTyrosine Kinase. Part 1: Hydroxynaphthalene Derivatives,”Bioorg. Med. Chem. Lett., 10:477-481 (2000).
Milkiewicz et al., “The Design, Synthesis and Activity of Non-ATP Competitive Inhibitors of pp60c-srcTyrosine Kinase. Part 2: Hydroxyindole Derivatives,”Bioorg. Med. Chem. Lett., 10:483-486 (2000).
Schelssinger, “New Roles for Src Kinases in Control of Cell Survival and Angiogenesis,”Cell, 100:293-296 (2000).
Sedlacek, “Kinase Inhibitors in Cancer Therapy,”Drugs, 59(3):435-476 (2000).
Susa et al., “Tyrosine Kinase Src Inhibitors: Potential Therapeutic Applications,”Drug News Perspect., 13(3):169-175 (2000).
Sridhar et al., “Protein Kinases as Therapeutic Targets,”Pharmaceutical Research, 17(11):1345-1353 (2000).
Biscardi, et al., “Tyrosine Kinase Signaling in Breast Cancer: Epiderman Growth Factor Receptor and c-Src Interactions in Breast Cancer,”Breast Cancer Res., 2:203-210 (2000).
Śuśa et al., “Src Inhibitors: Drugs for the Treatment of Osteoporosis, Cancer or Both?,”TiPS, 21:489-495 (2000).
Hubbard et al., “Protein Tyrosine Kinase Structure and Function,”Annu. Rev. Biochem., 69:373-398 (2000).
Fretz et al., “Structure-based Design of Compounds Inhibiting Grb2-SH2 Mediated Protein-Protein Interactions in Signal Transduction Pathways,”Current Pharmaceutical Design, 6(18):1777-1796 (2000) (Abstract).
Vu, “Recent Advances in the Design and Synthesis of SH2 Inhibitors of Src, Grb2 and ZAP-70,”Current Medicinal Chemistry, 7(10):1081-1100 (2000) (Abstract).
Haskell, et al., “c-Src Tyrosine Phosphorylation of Epidermal Growth Factor Receptor, P190 RhoGAP, and Focal Adhesion Kinase Regulates Diverse Cellular Processes,”Chemical Reviews, 101(8):2425-2440 (2001).
McCluskey et al., “Small Molecule Inhibitors of Serine/Threonine Protein Phosphatases,”Mini-Reviews in Medicinal Chemistry, 1(1):43-55 (2001) (Abstract).
Zhang, “Protein Tyrosine Phosphatases: Prospects for Therapeutics,”Current Opinion in Chemical Biology5(4):416-423 (2001) (Abstract).
Bridges, “ Chemical Inhibitors of Protein Kinases,”Chemical Reviews, 101(8):2541-2571 (2001).
Park et al., “Metabolism of Fluorine-Containing Drugs,”Annu. Rev. Pharmacol, Toxicol., 41:443-470 (2001).
Sawyer et al., “Src Inhibitors: Genomics to Therapeutics,”Expert Opin. Investg. Drugs, 10(7):1327-1344 (2001).
Blume-Jensen et al., “Oncogenic Kinase Signaling,”Nature, 411:355-365 (2001).
Martin, “Timeline: The Hunting of the Src,”Nat. Rev. Mol. Cell Biol., 2:467-475 (2001).
Garcia-Echeverria, “Antagonists of the Src Homology 2 (SH2) Domains of Grb2, Src, Lck and ZAP-70,”Current Medicinal Research, 8(13):1589-1604 (2001) (Abstract).
Muller, “Peptidomimetic SH2 Domain Antagonists for Targeting Signal Transduction,”Topics in Current Chemistry, 211:17-59 (2001) (Abstract).
Zhang, “Protein Tyrosine Phosphatases: Structure and Function, Substrate Specificity, and Inhibitor Development,”Annual Review of Pharmacology and Toxicology, 42:209-234 (2002) (Abstract).
McCluskey et al., “Serine-Threonine Protein Phosphatase Inhibitors: Development of Potential Therapeutic Strategies,”Journal of Medicinal Chemistry, 45(6):1151-1175 (2002) (Abstract).
Johnson et al., “Protein Tyrosine Phosphatase 1B Inhibitors for Diabetes,”Nat. Rev. Drg Discov., 1(9):696-709 (2002) (Abstract).
Frame, “Src in Cancer: Deregulation and Consequences for Cell Behavior,”Biochemica et Biophysica Acta, 1602:114-130 (2002).
Druker, “STI571 (Gleevec) as a Paradigm for Cancer Therapy,”Trends in Molecular Medicine, 8(4 Suppl):S14-18 (2002) (Abstract).
Bakhtiar et al., “Quantification of the Anti-Leukemia Drug STI1571 (Gleevec) and its Metabolite (CGP 74588) in Monkey Plasma Using a Semi-Automated Solid Phase Extraction Procedure and Liquid Chromatography-Tandem Mass Spectrometry,”Journal of Pharmaceutical&Biomedical Analysis, 28(6):1183-1194 (2002) (Abstract).
Burke et al., “Phosphotyrosyl Mimetics in the Development of Signal Transduction Inhibitors,”Acc. Chem. Res., 36:426-433 (2003).
Levitzki, “Protein Kinase Inhibitors as a Therapeutic Modality,”Acc. Chem. Res., 3
Hangauer, Jr. David G.
Henderson Donald
Nicotera Thomas
Elrifi Ivor R.
Erlacher Heidi A.
Health Research , Inc.
Mintz Levin Cohn Ferris Glovsky & Popeo P.C.
Saeed Kamal A
LandOfFree
Protection against and treatment of hearing loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection against and treatment of hearing loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection against and treatment of hearing loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3942405